Peripheral Corticotropin-Releasing Factor Triggers Jejunal Mast Cell Activation and Abdominal Pain in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
Journal
The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
3
8
2020
medline:
5
1
2021
entrez:
3
8
2020
Statut:
ppublish
Résumé
To determine the effect of peripheral CRF on intestinal barrier function in diarrhea-predominant IBS (IBS-D). Irritable bowel syndrome (IBS) pathophysiology has been linked to life stress, epithelial barrier dysfunction, and mast cell activation. Corticotropin-releasing factor (CRF) is a major mediator of stress responses in the gastrointestinal tract, yet its role on IBS mucosal function remains largely unknown. Intestinal response to sequential i.v. 5-mL saline solution (placebo) and CRF (100 μg) was evaluated in 21 IBS-D and 17 healthy subjects (HSs). A 20-cm jejunal segment was perfused with an isosmotic solution and effluents collected at baseline, 30 minutes after placebo, and 60 minutes after CRF. We measured water flux, albumin output, tryptase release, stress hormones, cardiovascular and psychological responses, and abdominal pain. A jejunal biopsy was obtained for CRF receptor expression assessment. Water flux did not change after placebo in IBS-D and HS but significantly increased after CRF in IBS-D (P = 0.007). Basal luminal output of albumin was higher in IBS-D and increased further after CRF in IBS-D (P = 0.042). Basal jejunal tryptase release was higher in IBS-D, and CRF significantly increased it in both groups (P = 0.004), the response being higher in IBS-D than in HS (P = 0.0023). Abdominal pain worsened only in IBS-D after CRF and correlated with jejunal tryptase release, water flux, and albumin output. IBS-D displayed jejunal up-regulation of CRF2 and down-regulation of CRF1 compared with HS. Stress via CRF-driven mast cell activation seems to be relevant in the pathophysiology of IBS-D.
Identifiants
pubmed: 32740086
doi: 10.14309/ajg.0000000000000789
pii: 00000434-202012000-00024
doi:
Substances chimiques
Corticotropin-Releasing Hormone
9015-71-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2047-2059Références
Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2006;101:1288–94.
Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007;56:203–9.
Martínez C, Vicario M, Ramos L, et al. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction-signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol 2012;107:736–46.
Wouters MM, Vicario M, Santos J. The role of mast cells in functional GI disorders. Gut 2016;65:155–68.
Marshall JK, Thabane M, Garg AX, et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004;20:1317–22.
Rao AS, Camilleri M, Eckert DJ, et al. Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls. Am J Physiol Gastrointest Liver Physiol 2011;301:G919–28.
Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators. Gut 2009;58:196–201.
Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009;146:41–6.
Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012;303:G775–85.
Zhou Q, Souba WW, Croce CM, et al. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut 2010;59:775–84.
Bertiaux-Vandaële N, Youmba SB, Belmonte L, et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol 2011;106:2165–73.
Martinez C, Lobo B, Pigrau M, et al. Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut 2013;62:1160–8.
Lee JW, Park JH, Park DI, et al. Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase. Dig Dis Sci 2010;55:2922–8.
Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009;137:1425–34.
Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007;117:636–47.
Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693–702.
Klooker TK, Braak B, Koopman KE, et al. The mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010;59:1213–21.
Lobo B, Ramos L, Martínez C, et al. Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study. United Eur Gastroenterol J 2017;5:887–97.
Wang J, Wang Y, Zhou H, et al. Clinical efficacy and safety of ketotifen in treating irritable bowel syndrome with diarrhea. Eur J Gastroenterol Hepatol 2020;32:706–12.
Mayer EA, Naliboff BD, Chang L, et al. Stress and irritable bowel syndrome. Am J Physiol 2001;280:G519–24.
Qin HY, Cheng CW, Tang XD, et al. Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol 2014;20:14126–31.
Surdea-Blaga T, Băban A, Dumitrascu DL. Psychosocial determinants of irritable bowel syndrome. World J Gastroenterol 2012;18:616–26.
Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? Gastroenterology 2002;122:1140–56.
Naliboff BD, Smith SR, Serpa JG, et al. Mindfulness-based stress reduction improves irritable bowel syndrome (IBS) symptoms via specific aspects of mindfulness. Neurogastroenterol Motil 2020:e13828.
Barclay GR, Turnberg LA. Effect of psychological stress on salt and water transport in the human jejunum. Gastroenterology 1987;93:91–7.
Barclay GR, Turnberg LA. Effect of cold-induced pain on salt and water transport in the human jejunum. Gastroenterology 1988;94:994–8.
Santos J, Saperas E, Nogueiras C, et al. Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology 1998;114:640–8.
Alonso C, Guilarte M, Vicario M, et al. Maladaptive intestinal epithelial responses to life stress may predispose healthy women to gut mucosal inflammation. Gastroenterology 2008;135:163–72.
Vanuytsel T, van Wanrooy S, Vanheel H, et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut 2014;63:1293–9.
Koob GF. Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 1999;46:1167–80.
Tache Y, Perdue MH. Role of peripheral CRF signalling pathways in stress-related alterations of gut motility and mucosal function. Neurogastroenterol Motil 2004;16:137–42.
Larauche M, Kiank C, Tache Y. Corticotropin releasing factor signaling in colon and ileum: Regulation by stress and pathophysiological implications. J Physiol Pharmacol 2009;60:33–46.
Kano M, Muratsubaki T, Van Oudenhove L, et al. Altered brain and gut responses to corticotropin-releasing hormone (CRH) in patients with irritable bowel syndrome. Sci Rep 2017;7:124–5.
Tayama J, Sagami Y, Shimada Y, et al. Effect of alpha-helical CRH on quantitative electroencephalogram in patients with irritable bowel syndrome. Neurogastroenterol Motil 2007;19:471–83.
Wallon C, Yang PC, Keita Av, et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008;57:50–8.
Holmes TH, Rahe RH. The social readjustment rating scale. J Psychosom Med 1967;11:213–8.
Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–71.
Spiegel B, Bolus R, Harris LA, et al. Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther 2009;30:1159–70.
Naliboff BD, Benton D, Solomon GF, et al. Immunological changes in young and old adults during brief laboratory stress. Psychosom Med 1991;53:121–32.
Muglia L, Jacobson L, Dikkes P, et al. Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature 1995;373:427–32.
Heitkemper M, Jarrett M, Cain K, et al. Increased urine catecholamines and cortisol in women with irritable bowel syndrome. Am J Gastroenterol 1996;91:906–13.
Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998;42:845–9.
Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: Plasma cytokines as a potential biomarker? Gastroenterology 2006;130:304–11.
Bohmelt AH, Nater UM, Franke S, et al. Basal and stimulated hypothalamic-pituitary-adrenal axis activity in patients with functional gastrointestinal disorders and healthy controls. Psychosom Med 2005;67:288–94.
Tanaka Y, Kanazawa M, Kano M, et al. Differential activation in amygdala and plasma noradrenaline during colorectal distention by administration of corticotropin-releasing hormone between healthy individuals and patients with irritable bowel syndrome. PLoS One 2016;11:e0157347.
Murray KA, Lam C, Rehman S, et al. Corticotropin-releasing factor increases ascending colon volume after a fructose test meal in healthy humans: A randomized controlled trial. Am J Clin Nutr 2016;103:1318–26.
Camilleri M. Leaky gut: Mechanisms, measurement and clinical implications in humans. Gut 2019;68:1516–26.
Zuo L, Kuo WT, Turner JR. Tight junctions as targets and effectors of mucosal immune homeostasis. Cell Mol Gastroenterol Hepatol 2020;10(2):327–40.
Fihn BM, Sjöqvist A, Jodal M. Permeability of the rat small intestinal epithelium along the villus-crypt axis: Effects of glucose transport. Gastroenterology 2000;119:1029–36.
Buschmann MM, Shen L, Rajapakse H, et al. Occludin OCEL-domain interactions are required for maintenance and regulation of the tight junction barrier to macromolecular flux. Mol Biol Cell 2013;24:3056–68.
Demaude J, Salvador-Cartier C, Fioramonti J, et al. Phenotypic changes in colonocytes following acute stress or activation of mast cells in mice: Implications for delayed epithelial barrier dysfunction. Gut 2006;55:655–61.
Yue H, Bin L, Chaoying C, et al. Potential regulatory effects of corticotropin-releasing factor on tight junction-related intestinal epithelial permeability are partially mediated by CK8 upregulation. Cell Physiol Biochem 2017;44:1161–73.
Seldin and Giebisch's The Kidney, 5th Edition. Physiology and Pathophysiology. In: Alpern RJ, Moe OW, Caplan M (eds.) Book ISBN: 9780123814623. Academic Press: San Diego, CA, 2012, pp 579.
Hashem L, Swedrowska M, Vllasaliu D. Intestinal uptake and transport of albumin nanoparticles: Potential for oral delivery. Nanomedicine (Lond) 2018;13:1255–65.
Hartmann P, Chen P, Wang HJ, et al. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology 2013;58:108–19.
Beeken WL. Clearance of circulating radiochromated albumin and erythrocytes by the gastrointestinal tract of normal subjects. Gastroenterology 1967;52:35–41.
Yuan PQ, Wu SV, Elliott J, et al. Expression of corticotropin releasing factor receptor type 1 (CRF1) in the human gastrointestinal tract and upregulation in the colonic mucosa in patients with ulcerative colitis. Peptides 2012;38:62–9.
Saunders PR, Maillot C, Million M, et al. Peripheral corticotropin-releasing factor induces diarrhea in rats: Role of CRF1 receptor in fecal watery excretion. Eur J Pharmacol 2002;435:231–5.
Keita AV, Söderholm JD, Ericson AC. Stress-induced barrier disruption of rat follicle-associated epithelium involves corticotropin-releasing hormone, acetylcholine, substance P, and mast cells. Neurogastroenterol Motil 2010;22:770–8.
Barreau F, Cartier C, Leveque M, et al. Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: Corticotrophin-releasing factor and nerve growth factor interplay. J Physiol 2007;580:347–56.
Overman EL, Rivier JE, Moeser AJ. CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-α. PLoS One 2012;7:e39935.
Santos J, Yates D, Guilarte M, et al. Stress neuropeptides evoke epithelial responses via mast cell activation in the rat colon. Psychoneuroendocrinology 2008;33:1248–56.
Sato N, Suzuki N, Sasaki A, et al. Corticotropin-releasing hormone receptor 1 gene variants in irritable bowel syndrome. PLoS One 2012;7:e42450.
Komuro H, Sato N, Sasaki A, et al. Corticotropin-releasing hormone receptor 2 gene variants in irritable bowel syndrome. PLoS One 2016;11:e0147817.
Udelsman R, Gallucci WT, Bacher J, et al. Hemodynamic effects of corticotropin releasing hormone in the anesthetized cynomolgus monkey. Peptides 1986;7:465–71.
Muramatsu Y, Fukushima K, Iino K, et al. Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa. Peptides 2000;21:1799–809.
Yuan PQ, Wu V, Chang L. Cellular localization of corticotropin-releasing factor (CRF) receptor 1 (CRF1) in human colon and its expression in the jejunum and colon of irritable bowel syndrome (IBS) female and male patients. Gastroenterology 2007;132:A190.
Sagami Y, Shimada Y, Tayama J, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004;53:958–64.
D'Costa S, Ayyadurai S, Gibson AJ, et al. Mast cell corticotropin-releasing factor subtype 2 suppresses mast cell degranulation and limits the severity of anaphylaxis and stress-induced intestinal permeability. J Allergy Clin Immunol 2019;143:1865–77.
Ayyadurai S, Gibson AJ, D'Costa S, et al. Frontline science: Corticotropin-releasing factor receptor subtype 1 is a critical modulator of mast cell degranulation and stress-induced pathophysiology. J Leukoc Biol 2017;102:1299–312.
Greetfeld M, Schmidt MV, Ganea K, et al. A single episode of restraint stress regulates central corticotrophin-releasing hormone receptor expression and binding in specific areas of the mouse brain. J Neuroendocrinol 2009;21:473–80.
Brunson KL, Grigoriadis DE, Lorang MT, et al. Corticotropin-releasing hormone (CRH) downregulates the function of its receptor (CRF1) and induces CRF1 expression in hippocampal and cortical regions of the immature rat brain. Exp Neurol 2002;176:75–86.
Hauger RL, Risbrough V, Oakley RH, et al. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann N Y Acad Sci 2009;1179:120–43.
Waters RP, Rivalan M, Bangasser DA, et al. Evidence for the role of corticotropin-releasing factor in major depressive disorder. Neurosci Biobehav Rev 2015;58:63–78.
Pritchard SE, Garsed KC, Hoad CL, et al. Effect of experimental stress on the small bowel and colon in healthy humans. Neurogastroenterol Motil 2015;27:542–9.
Keita AV, Carlsson AH, Cigéhn M, et al. Vasoactive intestinal polypeptide regulates barrier function via mast cells in human intestinal follicle-associated epithelium and during stress in rats. Neurogastroenterol Motil 2013;25:e406–17.
Masini E, Fantozzi R, Blandina P, et al. The riddle of cholinergic histamine release from mast cells. In: Ellis GP, West GB (eds.) Progress in Medicinal Chemistry. Vol 22. Amsterdam: Elsevier Science Publishers BV, 1985, pp 267–91.
Wallon C, Persborn M, Jönsson M, et al. Eosinophils express muscarinic receptors and corticotropin-releasing factor to disrupt the mucosal barrier in ulcerative colitis. Gastroenterology 2011;140:1597–607.
Zheng PY, Feng BS, Oluwole C, et al. Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine. Gut 2009;58:1473–9.